Article

Collection of Family Cancer History Is Suboptimal, Highlighting Need for Patient Reporting

Author(s):

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal — highlighting the need to optimize online collection with a provider-free approach, according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

“The biggest gap is in capturing the age of diagnosis for the family members who are affected by cancer,” explained Dr. Mala Pande, an assistant professor in the Department of Gastroenterology, Hepatology and Nutrition at The University of Texas MD Anderson Cancer Center in Houston, in an interview with CURE.

While family history is one of the key indicators of hereditary cancers — such as colorectal, endometrial, stomach, breast, ovarian, intestinal, pancreatic, prostate, urinary tract, liver, kidney and bile duct cancers — previous research has shown that family cancer history documentation has been suboptimal.

“When you really look at the utility of family cancer history, it is to run a risk assessment to see if genetic testing or genetic referral is required for the patient,” Pande said. “If you don't have a complete family history, it's not possible to run an accurate risk assessment. It really makes it important to have a good family history captured in the electronic health record.”

Therefore, she and her colleagues evaluated the quality of family cancer history as entered by the patient into the electronic health record to determine its competency in determining Lynch Syndrome risk assessment.

“We basically wanted to really take on this project to be able to increase ascertainment of these high-risk cases,” Pande said. “With that in mind, family history speaks to the fact that people may be at high risk if they have more than one family member affected in their family.”

Family cancer history was self-reported by all new patients, from September 2016 to August 2017, using an online, patient-facing, custom created questionnaire sent days ahead of their appointments. The questionnaire was then reviewed and/or updated by a clinic nurse during the first physician visit. Last, the results were imported into the electronic health record’s review of systems.

The researchers determined the quality of family cancer history attainment by calculating the rates of three reported variables (first/second degree of kinship, cancer site/type and age at diagnosis) required for PREMM5 (PREdiction Model for gene Mutations), a risk-prediction model for Lynch Syndrome.

Of 47,647 new patients, 47.5% reported with family cancer history in one or more relatives — including 46.1% who were first degree, 64.8% who were second degree, 3.0% considered other and 2.4% that were missing. When evaluating the status of family history in the electronic health record in this group, 42.2% reported their relative’s specific cancer and 10.3% with their age at diagnosis – leading to 9.9% of patients who were evaluable for Lynch Syndrome with PREMM5.

When evaluating the three elements of family cancer history for evaluation by PREMM5, family history was reported in 97.6%, a cancer type/site was specified for 88.8% reporting family cancer history, and age at diagnosis was listed for 21.7% of their relatives’ cancers. In total, only 20.9% of patients reported with a family history, the specific cancer type/site and age at diagnosis. Moreover, fewer men (9.5%) than women (28.1%) provided all three family cancer history elements.

Lastly, 46.7% of patients with breast cancer, 21.9% of patients with gastrointestinal cancer, 47.2% of those seen for cancer prevention screening and 23.1% of patients undergoing an endoscopy reported all three elements; however, the researchers observed lower rates for the other cancer types.

The researchers noted that these results underscore the need to optimize patient-facing reporting of family cancer history using online tools for an automated risk-assessment that removes the providers’ collection of information, adding that this approach may also include patient education and electronic health record prompts for family history completion.

“The best person to report on the family history is the patient themselves. If they can do it in advance, then they are more likely to have more complete information and more complete details of their family history,” Pande said.

Related Videos
Image of bald man.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Related Content